AstraZeneca: EU approves Tagrisso in lung cancer

(CercleFinance.com) - AstraZeneca announced on Monday that the European Union has approved Tagrisso in patients with EGFR-mutated advanced non-small cell lung cancer.


The biopharmaceutical group reports that the European Commission has approved its drug for the treatment of locally advanced, non-operable non-small cell lung cancer (NSCLC) with a deletion in exon 19 or a substitution mutation in exon 21 (L858R) of the epidermal growth factor receptor (EGFR) gene.

This green light applies to patients whose disease has not progressed following or during platinum-based chemo-radiotherapy.

The laboratory adds that approval of Tagrisso was granted in light of the results of the Phase III clinical trial, which showed that Tagrisso reduced the risk of death or disease progression by 84% compared with placebo.

Median progression-free survival was 39.1 months in the Tagrisso group, versus 5.6 months in the placebo group.

Copyright (c) 2024 CercleFinance.com. All rights reserved.